Toggle light / dark theme

The Human Genome Project is probably the most ambitious scientific proposal ever made.


ii. writing DNA

Synthesising short, single stranded fragments of DNA, called oligonucleotides (oligos for short) has been automated and affordable for a number of years now, and almost every biology laboratory in the world uses these short fragments (usually 18–25 base-pairs — compare this to the human genome which is 3 billion base-pairs long) for applications ranging from disease diagnostics to making genetically modified plants. What really has been a game-changer in DNA synthesis is the ability to synthesise longer pieces of DNA and the ability to join these together efficiently to form synthetic gene length fragments.

This ability to synthesise DNA quickly and cheaply has excited a group of biologists who want to use it to create entire genomes from scratch. To study life by building it, gene by gene. Going further, scientists want to create a “minimal genome” to identify exactly only those genes absolutely necessary to support the most basic form of life. Genome synthesis could also enable us to create optimised strains of biological workhorses like yeast, to more efficiently produce pharmaceuticals and fuels. These ambitions have fuelled the field of synthetic genomics, beginning with the synthesis of a Mycoplasma mycoides genome by Craig Venter in 2008.

How close are we to creating a synthetic human genome?


Creating humans is also an ethical minefield. Unsettled questions about who might own a synthetic human genome abound. Boeke warns that ownership could come down to who ends up funding the project development. Rob Carlson, a co-author of the GP-Write proposal, is even more skeptical of the idea of a patented artificial human genome, pointing out via email that “as soon as there is any possibility of a synthetic genome being used to germinate a live human, then ownership is obviously out of the question anyway…because you are now talking about owning a person.”

So far the GP-write project has been more talk than action, with large consultation meetings held between scientists and policy experts. The project has yet to attract significant funding. Perhaps successes in other organisms like yeast will embolden governments and private industry to open up to the idea of a man-made human genome.

Given that building a genome is so technically demanding, and with uncertain rewards, I’ve often wondered why anyone might want to undertake such a venture. Some, like Boeke, seem to be in it mainly for the science — for the questions that can only be answered by building life from scratch. Others, like Harvard geneticist George Church, a genome sequencing pioneer and co-author of the GP-write proposal, are more excited by the potential life-changing applications. In any case, it’s clear that writing genomes is the next major scientific frontier — and that we’re well on our way to crossing it.

Afghanistan’s first-ever robot waitress glides up to a table of curious diners in central Kabul and presents them with a plate of French fries.

“Thank you very much,” the machine says in Dari, one of Afghanistan’s two main languages.

Restaurant manager Mohammad Rafi Shirzad says the humanoid robot, imported from Japan and designed to look vaguely like a women wearing a hijab, has already pulled in new customers since it started working last month.

Newborn screening covers more than 30 conditions. Yet, with genome sequencing, we could screen newborns for several thousand genetic conditions.


In the surveys’ open-ended responses about risks of genome sequencing, parents and clinicians both expressed concerns about psychological distress related to difficult or uncertain results. Clinicians were more likely to raise concerns about returning results for adult-onset conditions, unnecessary parental stress over health problems that might never actually occur, and the possibility of future discrimination against the child on the basis of their genomic information.

On the other hand, parents mentioned a broader range of benefits than clinicians. Both parents and clinicians saw potential health benefits of genome sequencing, such as the ability to search for more conditions compared to standard newborn screening and the ability to predict a child’s future disease risks. Parents went further, though, seeing benefits in family planning, preparing for the child’s future, and knowledge just for the sake of knowing. Those potential benefits fall outside of traditional definitions of clinical utility, which means they are less likely to be considered in the professional guidelines that steer adoption of practices like genome sequencing.

This brings us into a debate that may be central to the near future of genome sequencing, not only for newborns but for ostensibly healthy adults as well: how to define the utility of genomic technologies. How much weight, if any, should patients’ perceptions carry? If they think genomic information will have utility, should that count for something, even if clinicians and researchers have their doubts? Should the idea of “clinical utility” be expanded beyond information that directly affects medical care, perhaps including perceived quality of life impacts for patients?

Superb piece.

“But, I say we should pursue science and technology because, like Prometheus, the fires of invention burn bright, and although we may not always know where it leads us, a world darkened by the fear of treading upon the unknown, is unimaginable.”


Yet we can look to a brighter side, one I could never have imagined in the ’60’s when the chromosomes we karyotyped would be uncoiled to lay bare the genome as an instrument for critical medical diagnoses, to set free those erroneously convicted of crime, or enlighten us about Mitochondrial Eve our common mother, and the long journey that began two hundred thousand years ago; the journey that brought me into the world of physical things, air, table and chairs, and beyond into the space of the geometries and cohorts, like Golay and Bolsey, who helped me better understand my Universe, the one either too small or too far to see, unless aided by the eyes of science and technology. I once wondered how I got here, and now I think I know, but I am afraid my second query, “where will it lead,” will remain an open question.

One cannot predict with any precision where technology will lead us, although it has the indisputable potential to reduce suffering, extend life, and increase living standards. And, in the hands of the powerful, we witness its misuse altering natural patterns: ecosystems, the sustainability of organisms, to kill with greater efficiency. If we were separated from modern inventions, we would remain alive not more than a few days, weeks for survivalists. Invention does not only express our ingenuity, it expresses a societal conscience commensurate with the kind of world we collectively choose to live in.

Ingenuity itself has little control over where it leads, and I have long wondered whether one might in the words of Hamlet, “bear those ills we have than fly to others that we know not of.” But, I say we should pursue science and technology because, like Prometheus, the fires of invention burn bright, and although we may not always know where it leads us, a world darkened by the fear of treading upon the unknown, is unimaginable.

An auditory illusion thought to synchronize brain waves and alter mood is no more effective than other sounds, according to research in adults recently published in eNeuro. The effect reported in other studies might be a placebo but could still have helpful effects for some people.

Binaural beats are an auditory illusion caused by listening to two tones of slightly different frequency, one in each ear. The difference in frequencies creates the illusion of a third sound — a rhythmic beat. Neurons throughout the brain begin to send electrical messages at the same rate as the imaginary beat. Many unsupported claims surround binaural beats, including that listening to them decreases anxiety, increases focus, and improves mood.

Orozco Perez et al. played binaural and monoaural beats to healthy adults and measured their brain activity with electroencephalography. Monoaural beats don’t rely on the illusion to create the beats because they consist of edited audio tracks of the two different tones together. Both ears hear all three sounds. Brain activity synchronized with both types of beats, but the effect was stronger with monoaural beats. Neither type of beat affected mood. When the binaural beat played, far apart brain areas synchronized with each other at a different frequency than the beat. This may be how binaural beats improve memory and focus.

HUNTSVILLE, Ala. — Blue Origin formally opened a factory Feb. 17 that the company plans to use to produce engines both for its vehicles and for United Launch Alliance’s Vulcan rocket.

A ribbon-cutting ceremony marked the completion of a 350,000-square-foot factory here that will produce BE-4 and BE-3U engines. The factory, built in a little more than a year, will host more than 300 employees and produce up to 42 engines a year.

“You can see we can get some things done really quickly,” said Bob Smith, chief executive of Blue Origin, in remarks at the ceremony. “Twelve months to actually build this kind of facility is an amazing accomplishment for our team.”